Condition
Androgen Receptor Abnormal
Total Trials
4
Recruiting
0
Active
0
Completed
1
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 4 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 1 completed with results
Key Signals
100% success
Data Visualizations
Phase Distribution
1Total
P 2 (1)
Trial Status
Unknown2
Completed1
Withdrawn1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (4)
Showing 4 of 4 trials
NCT04368897Withdrawn
In-vitro Diagnostic Test to Predict COVID-19 Mortality and Disease Severity
NCT05157373UnknownPrimary
The Effect of Androgen Receptor Polymorphism on Endometrial Cancer
NCT04710186UnknownPrimary
AR, IGF-IR, IR and Peripheral Artery Disease
NCT03297385Phase 2Completed
Dynamics of Androgen Receptor Genomics and Transcriptomics After Neoadjuvant Androgen Ablation
Showing all 4 trials